Efficacy of Amlodipine/Olmesartan ± Hydrochlorothiazide in Patients Uncontrolled on Prior Calcium Channel Blocker or Angiotensin II Receptor Blocker Monotherapy

被引:3
作者
Neutel, Joel [1 ]
Shojaee, Ali [2 ]
Maa, Jen-Fue [2 ]
机构
[1] Orange Cty Res Ctr, Dept Clin Pharmacol, Tustin, CA 92780 USA
[2] Daiichi Sankyo Inc, Parsippany, NJ USA
关键词
Amlodipine; Angiotensin II receptor blocker; Blood pressure; Calcium channel blocker; Combination therapy; Hydrochlorothiazide; Hypertension; Olmesartan medoxomil; OLMESARTAN MEDOXOMIL; BLOOD-PRESSURE; COMBINATION; AMLODIPINE; TRIAL;
D O I
10.1007/s12325-012-0030-z
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
While monotherapy is often recommended as initial treatment, most patients require dose escalation and add-on agents to achieve their blood pressure (BP) goal. This secondary analysis evaluated the efficacy and safety of initiating patients on a regimen of fixed-dose amlodipine (AML)/olmesartan medoxomil (OM) +/- hydrochlorothiazide (HCTZ) who were uncontrolled on prior monotherapy with a calcium channel blocker (CCB) or angiotensin II receptor blocker (ARB). Patients uncontrolled on prior monotherapy with CCB or ARB therapy were initiated on AML/OM 5/20 mg and up-titrated every 4 weeks to AML/OM 5/40 mg, AML/OM 10/40 mg, AML/OM 10/40 + HCTZ 12.5 mg, and AML/OM 10/40 + HCTZ 25 mg. Patients were up-titrated to a higher AML/OM dose if mean seated cuff BP (SeBP) was a parts per thousand yen120/70 mmHg, and up-titrated to any HCTZ dose if mean SeBP was a parts per thousand yen125/75 mmHg. The primary efficacy endpoint was the cumulative proportion of patients achieving a seated cuff systolic BP (SeSBP) goal of < 140 mmHg (< 130 mmHg for patients with diabetes) after 12 weeks. Secondary endpoints included mean change from baseline in SeBP and ambulatory BP, ambulatory BP target achievement, and safety. For the prior CCB (n = 118; baseline SeBP: 153.4/91.5 mmHg) and ARB (n = 237; 154.6/92.6 mmHg) groups, SeSBP goal achievement after 12 weeks was 72.7% and 76.9%, respectively. Mean changes (+/- SE) from baseline in SeBP were dose proportional for prior CCB and ARB patients, ranging from -9.9 (+/- 1.25)/-5.8 (+/- 0.83) mmHg and -13.9 (+/- 0.79)/-7.6 (+/- 0.47) mmHg at the AML/OM 5/20 mg dose, respectively, to -21.8 (+/- 1.68)/-11.6 (+/-.12) mmHg and -26.2 (+/- 1.31)/-15.0 (+/- 0.86) mmHg at the AML/OM 10/40 mg + HCTZ 25 mg dose (P < 0.0001 for all). An AML/OM-based titration regimen was efficacious in achieving BP goal in patients uncontrolled on prior monotherapy with a CCB or ARB.
引用
收藏
页码:508 / 523
页数:16
相关论文
共 50 条
[41]   Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients [J].
Toh, Norihisa ;
Ishii, Katsuhisa ;
Kihara, Hajime ;
Iwakura, Katsuomi ;
Watanabe, Hiroyuki ;
Yoshikawa, Junichi ;
Ito, Hiroshi .
CIRCULATION JOURNAL, 2016, 80 (02) :426-+
[42]   Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II Study) [J].
Yamashita, Takeshi ;
Inoue, Hiroshi ;
Okumura, Ken ;
Kodama, Itsuo ;
Aizawa, Yoshifusa ;
Atarashi, Hirotsugu ;
Ohe, Tohru ;
Ohtsu, Hiroshi ;
Kato, Takao ;
Kamakura, Shiro ;
Kumagai, Koichiro ;
Kurachi, Yoshihisa ;
Koretsune, Yukihiro ;
Saikawa, Tetsunori ;
Sakurai, Masayuki ;
Sato, Toshiaki ;
Sugi, Kaoru ;
Nakaya, Haruaki ;
Hirai, Makoto ;
Hirayama, Atsushi ;
Fukatani, Masahiko ;
Mitamura, Hideo ;
Yamazaki, Tsutomu ;
Watanabe, Eiichi ;
Ogawa, Satoshi .
EUROPACE, 2011, 13 (04) :473-479
[43]   Combination of direct rennin inhibitor - aliskiren, angiotensin II receptor blocker - valsartan, and calcium channel blocker - amlodipine, in therapy of hypertensive patient with gout (case report) [J].
Dralova, O. V. ;
Maksimov, M. L. .
RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2011, 7 (04) :468-472
[44]   Effect of an angiotensin II receptor blocker and a calcium channel blocker on hypertension associated penile dysfunction in a rat model [J].
Shimizu, Shogo ;
Tsounapi, Panagiota ;
Honda, Masashi ;
Dimitriadis, Fotios ;
Taniuchi, Keisuke ;
Shimizu, Takahiro ;
Inoue, Keiji ;
Saito, Motoaki .
BIOMEDICAL RESEARCH-TOKYO, 2014, 35 (03) :215-221
[45]   Angiotensin II receptor blocker combined with eplerenone or hydrochlorothiazide for hypertensive patients with diabetes mellitus [J].
Karashima, Shigehiro ;
Yoneda, Takashi ;
Kometani, Mitsuhiro ;
Ohe, Masashi ;
Mori, Shunsuke ;
Sawamura, Toshitaka ;
Furukawa, Kenji ;
Yamagishi, Masakazu ;
Takeda, Yoshiyu .
CLINICAL AND EXPERIMENTAL HYPERTENSION, 2016, 38 (07) :565-570
[46]   Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats [J].
Nakamoto, T ;
Harasawa, H ;
Akimoto, K ;
Hirata, H ;
Kaneko, H ;
Kaneko, N ;
Sorimachi, K .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 528 (1-3) :43-51
[47]   Impact of the combination of an angiotensin II receptor blocker and low-dose hydrochlorothiazide on patients with morning hypertension [J].
Cheng, Xian Wu ;
Murohara, Toyoaki .
HYPERTENSION RESEARCH, 2012, 35 (07) :702-703
[48]   Urinary Albumin Excretion During Angiotensin II Receptor Blockade: Comparison of Combination Treatment With a Diuretic or a Calcium-Channel Blocker [J].
Matsui, Yoshio ;
Eguchi, Kazuo ;
Ishikawa, Joji ;
Shimada, Kazuyuki ;
Kario, Kazuomi .
AMERICAN JOURNAL OF HYPERTENSION, 2011, 24 (04) :466-473
[49]   A novel molecule of the angiotensin II receptor blocker class: Focus on olmesartan medoxomil [J].
Volpe M. ;
Trimarco B. .
High Blood Pressure & Cardiovascular Prevention, 2005, 12 (2) :79-89
[50]   Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial [J].
Ogihara, Toshio ;
Saruta, Takao ;
Rakugi, Hiromi ;
Saito, Ikuo ;
Shimamoto, Kazuaki ;
Matsuoka, Hiroaki ;
Teramukai, Satoshi ;
Higaki, Jitsuo ;
Ito, Sadayoshi ;
Shimada, Kazuyuki .
HYPERTENSION RESEARCH, 2015, 38 (01) :89-96